Nakatsukasa Yoshihiko, Yamada Yosuke, Yamada Yasuhiro
Department of Molecular Pathology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Regen Ther. 2024 Nov 27;28:12-19. doi: 10.1016/j.reth.2024.11.008. eCollection 2025 Mar.
The successful generation of induced pluripotent stem cells (iPSCs) has significantly impacted many scientific fields. In the field of regenerative medicine, iPSC-derived somatic cells are expected to recover impaired organ functions through cell transplantation therapy. Subsequent studies using genetically engineered mouse models showed that somatic cells are also reprogrammable . Notably, cyclic expression of reprogramming factors, so-called partial reprogramming ameliorates cellular and physiological hallmarks of aging without inducing teratoma formation or premature death of animals. Subsequent studies provided evidence supporting the beneficial effects of partial reprogramming in various organs. Although reprogramming appears to be a promising strategy for tissue regeneration and rejuvenation, there remain unsolved issues that hinder its clinical application, including concerns regarding its safety, controllability, and unexpected detrimental effects. Here, we review the pathway that research of reprogramming has followed and discuss the future perspective as we look toward its clinical application in regenerative medicine.
诱导多能干细胞（iPSC）的成功产生对许多科学领域产生了重大影响。在再生医学领域，iPSC衍生的体细胞有望通过细胞移植疗法恢复受损的器官功能。随后使用基因工程小鼠模型进行的研究表明，体细胞也具有重编程能力。值得注意的是，重编程因子的循环表达，即所谓的部分重编程，可改善衰老的细胞和生理特征，而不会诱导畸胎瘤形成或动物过早死亡。随后的研究提供了证据，支持部分重编程在各个器官中的有益作用。尽管重编程似乎是组织再生和年轻化的一种有前景的策略，但仍存在一些阻碍其临床应用的未解决问题，包括对其安全性、可控性和意外有害影响的担忧。在这里，我们回顾了重编程研究的历程，并展望其在再生医学临床应用中的未来前景。
